Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

Research output: Contribution to journalReview article

158 Citations (Scopus)

Abstract

Several lines of evidence implicate NMDA receptor dysfunction in the cognitive deficits of schizophrenia, suggesting that pharmacological manipulation of the NMDA receptor may be a feasible therapeutic strategy for treatment of these symptoms. Although direct manipulation of regulatory sites on the NMDA receptor is the most obvious approach for pharmacological intervention, targeting the G-protein coupled metabotropic glutamate (mGlu) receptors may be a more practical strategy for long-term regulation of abnormal glutamate neurotransmission. Heterogeneous distribution, both at structural and synaptic levels, of at least eight subtypes of mGlu receptors suggests that selective pharmacological manipulation of these receptors may modulate glutamatergic neurotransmission in a regionally and functionally distinct manner. Two promising targets for improving cognitive functions are mGlu5 or mGluR2/3 receptors, which can modulate the NMDA receptor-mediated signal transduction by pre- or postsynaptic mechanisms. Preclinical studies indicate that activation of these subtypes of mGlu receptors may be an effective strategy for reversing cognitive deficits resulting form reduced NMDA receptor mediated neurotransmission.

Original languageEnglish (US)
Pages (from-to)39-44
Number of pages6
JournalPsychopharmacology
Volume174
Issue number1
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Neurobehavioral Manifestations
Metabotropic Glutamate Receptors
N-Methyl-D-Aspartate Receptors
Schizophrenia
Synaptic Transmission
Pharmacology
GTP-Binding Proteins
Cognition
Glutamic Acid
Signal Transduction

Keywords

  • G-protein coupled receptors
  • Glutamate receptors
  • NMDA receptor dysfunction
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. / Moghaddam, Bita.

In: Psychopharmacology, Vol. 174, No. 1, 06.2004, p. 39-44.

Research output: Contribution to journalReview article

@article{536a855237de4e2fb8ef2e63bc2a628d,
title = "Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia",
abstract = "Several lines of evidence implicate NMDA receptor dysfunction in the cognitive deficits of schizophrenia, suggesting that pharmacological manipulation of the NMDA receptor may be a feasible therapeutic strategy for treatment of these symptoms. Although direct manipulation of regulatory sites on the NMDA receptor is the most obvious approach for pharmacological intervention, targeting the G-protein coupled metabotropic glutamate (mGlu) receptors may be a more practical strategy for long-term regulation of abnormal glutamate neurotransmission. Heterogeneous distribution, both at structural and synaptic levels, of at least eight subtypes of mGlu receptors suggests that selective pharmacological manipulation of these receptors may modulate glutamatergic neurotransmission in a regionally and functionally distinct manner. Two promising targets for improving cognitive functions are mGlu5 or mGluR2/3 receptors, which can modulate the NMDA receptor-mediated signal transduction by pre- or postsynaptic mechanisms. Preclinical studies indicate that activation of these subtypes of mGlu receptors may be an effective strategy for reversing cognitive deficits resulting form reduced NMDA receptor mediated neurotransmission.",
keywords = "G-protein coupled receptors, Glutamate receptors, NMDA receptor dysfunction, Schizophrenia",
author = "Bita Moghaddam",
year = "2004",
month = "6",
language = "English (US)",
volume = "174",
pages = "39--44",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

AU - Moghaddam, Bita

PY - 2004/6

Y1 - 2004/6

N2 - Several lines of evidence implicate NMDA receptor dysfunction in the cognitive deficits of schizophrenia, suggesting that pharmacological manipulation of the NMDA receptor may be a feasible therapeutic strategy for treatment of these symptoms. Although direct manipulation of regulatory sites on the NMDA receptor is the most obvious approach for pharmacological intervention, targeting the G-protein coupled metabotropic glutamate (mGlu) receptors may be a more practical strategy for long-term regulation of abnormal glutamate neurotransmission. Heterogeneous distribution, both at structural and synaptic levels, of at least eight subtypes of mGlu receptors suggests that selective pharmacological manipulation of these receptors may modulate glutamatergic neurotransmission in a regionally and functionally distinct manner. Two promising targets for improving cognitive functions are mGlu5 or mGluR2/3 receptors, which can modulate the NMDA receptor-mediated signal transduction by pre- or postsynaptic mechanisms. Preclinical studies indicate that activation of these subtypes of mGlu receptors may be an effective strategy for reversing cognitive deficits resulting form reduced NMDA receptor mediated neurotransmission.

AB - Several lines of evidence implicate NMDA receptor dysfunction in the cognitive deficits of schizophrenia, suggesting that pharmacological manipulation of the NMDA receptor may be a feasible therapeutic strategy for treatment of these symptoms. Although direct manipulation of regulatory sites on the NMDA receptor is the most obvious approach for pharmacological intervention, targeting the G-protein coupled metabotropic glutamate (mGlu) receptors may be a more practical strategy for long-term regulation of abnormal glutamate neurotransmission. Heterogeneous distribution, both at structural and synaptic levels, of at least eight subtypes of mGlu receptors suggests that selective pharmacological manipulation of these receptors may modulate glutamatergic neurotransmission in a regionally and functionally distinct manner. Two promising targets for improving cognitive functions are mGlu5 or mGluR2/3 receptors, which can modulate the NMDA receptor-mediated signal transduction by pre- or postsynaptic mechanisms. Preclinical studies indicate that activation of these subtypes of mGlu receptors may be an effective strategy for reversing cognitive deficits resulting form reduced NMDA receptor mediated neurotransmission.

KW - G-protein coupled receptors

KW - Glutamate receptors

KW - NMDA receptor dysfunction

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=3142739322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142739322&partnerID=8YFLogxK

M3 - Review article

C2 - 15205877

AN - SCOPUS:3142739322

VL - 174

SP - 39

EP - 44

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -